Eli Lilly's 48% Q2 Jump Looks Great-But the Real Test Starts After the Guidance Hike

The quarter was solid, but the benchmark just got higher

A strong report came with heavier expectations

Lilly's second quarter was strong enough to settle the near-term execution debate. The company delivered a 39.4% EPS beat, grew revenue 48%, and raised 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion. That combination matters because a guidance raise after an already strong quarter usually suggests demand remains healthy rather than fading.

The core drivers were still there: Zepbound and Mounjaro continued to power growth. For investors, the bigger takeaway is not the headline beat itself but the fact that Lilly now expects that strength to carry further into the full year.

The next report will be judged against a higher bar

This is where expectations matter most. Bulls can point to the latest beat, the raised outlook, and the fact that the stock rose 4% in morning trading as evidence that momentum may continue. Bears have a more structural argument: once investors anchor to $85 billion-$87 billion in 2026 revenue, future results are judged against a higher ceiling.

That is why the next update matters so much. On Oct. 29, 2026, Lilly shifts from proving it can execute to proving it can keep outrunning elevated expectations.